Paulina Carpinteyro-Espin

Dr. Paulina Carpinteyro-Espin

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2022 in Anz Journal of Surgery
Verified
Journal Article
Closed access
PCPaulina Carpinteyro-Espin
Paulina Carpinteyro-Espin
OSOscar Santes
Oscar Santes
PMPaulina Moctezuma‐Velazquez
Paulina Moctezuma‐Velazquez
JNJulio A. Navarro‐Iñiguez
Julio A. Navarro‐Iñiguez
ANAdolfo Navarro‐Navarro
Adolfo Navarro‐Navarro
NSNoel Salgado‐Nesme
Noel Salgado‐Nesme

19 May 2025 in Life
Verified
Journal Article
Open access
PDF file
AHAline Huerta
Aline Huerta
MAMariana Arellano
Mariana Arellano
CCClyo Anahí Chávez-Méndez
Clyo Anahí Chávez-Méndez
PCPaulina Carpinteyro-Espin
Paulina Carpinteyro-Espin
CPCarmen Palacios-Reyes
Carmen Palacios-Reyes
JPJuanita Pérez-Escobar
Juanita Pérez-Escobar
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease, linked closely to metabolic syndrome and rising obesity rates. Affecting up to 37% of the global adult population, MASLD prevalence is exceptionally high among individuals of Hispanic descent, with genetic factors such as the PNPLA3 gene mutation playing a significant role. The subject of this review is the traditional Mesoamerican “milpa” diet, which includes unprocessed local crops like maize, beans, pumpkins, chili, and tomatoes and may represent a strategy to combat MASLD. Current treatment recommendations emphasize weight loss; a reduced intake of saturated fats, processed meats, and added sugars; and increased physical activity. The milpa diet, rich in protein, fiber, vitamins, and bioactive compounds, aligns with these recommendations and could potentially mitigate MASLD by preventing liver fat accumulation and fibrosis. This narrative review focuses on available preclinical and clinical studies adopting the milpa diet as a culturally relevant, nutritious, and sustainable dietary approach in preventing and treating MASLD. More clinical studies are needed to develop precise nutritional quantitative recommendations and guidelines.

20 August 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
JGJosé Carlos Gasca
José Carlos Gasca
JCJesús Enrique Castrejón-Sánchez
Jesús Enrique Castrejón-Sánchez
MFMario Carrasco Flores
Mario Carrasco Flores
Enzo Vasquez JimenezEnzo Vasquez Jimenez
Enzo Vasquez Jimenez
PCPaulina Carpinteyro-Espin
Paulina Carpinteyro-Espin
PCPaula Costa-Urrutia
Paula Costa-Urrutia
Background/Objectives: Acute liver failure (ALF) is a life-threatening condition with high mortality in nontransplant candidates. Therapeutic plasma exchange (TPE) has emerged as a promising intervention for removing inflammatory mediators and toxic metabolites. In Latin America, data on the efficacy of TPE in ALF patients are limited. This real-world study aimed to compare 30-day survival outcomes between patients receiving standard medical treatment (SMT) and those receiving SMT plus TPE. Methods: We analyzed 25 ALF patients admitted to the tertiary intensive care unit (ICU) of Hospital Juárez of Mexico City, Mexico, from 2018 to 2024. Patients received either standard medical treatment (SMT group, n = 12) or SMT with TPE (TPE group, n = 13), including high-volume TPE (n = 8) and standard-volume TPE (n = 5). Survival analysis was performed via Kaplan–Meier estimates, and binomial regression analysis was run to estimate the mortality probability stratified by the hepatic encephalopathy grade. Results: At 30 days, survival was significantly greater in the TPE group (92%) than in the SMT group (50%) (p = 0.02). The greatest survival benefit was observed in patients with Grade 4 encephalopathy. The ICU stay was longer in the TPE group, reflecting the complexity of ALF management. Conclusions: TPE significantly improves 30-day survival in ALF patients compared with SMT alone, supporting its role as an adjunct therapy. Further studies are needed to refine patient selection and optimize treatment protocols.

7 October 2025 in World Journal of Gastroenterology
Verified
Journal Article
Closed access
JPJuanita Pérez-Escobar
Juanita Pérez-Escobar
AHAline Huerta-Álvarez
Aline Huerta-Álvarez
GCGraciela Elia Castro-Narro
Graciela Elia Castro-Narro
MAMaría Isabel Astudillo-Delgado
María Isabel Astudillo-Delgado
PCPaulina Carpinteyro-Espin
Paulina Carpinteyro-Espin
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a silent epidemic having substantial clinical implications, with liver transplantation being one of the areas most impacted. The increasing prevalence of metabolic fatty liver disease has reduced the quality of available donor organs. While noninvasive methods are increasingly applied to evaluate liver steatosis in deceased donors, liver biopsy remains the gold standard. Many aspects of liver biopsies are not yet fully standardized. Macrovesicular hepatic steatosis is associated with decreased allograft quality and poorer short- and long-term transplant outcomes, especially in moderate and severe steatotic cases. Donation after cardiac arrest further exacerbates these poor outcomes. Matching marginal allografts with suitable recipients based on recipient characteristics is crucial for improving transplant outcomes. Living donor liver transplant is a feasible option for addressing organ shortages. Noninvasive evaluation is preferred for assessing liver health; however, when the results are inconclusive, a liver biopsy is recommended. Lifestyle modifications can improve graft, living donor and recipient outcomes. Analysis of the impact of MASLD on the donor pool and the implementation of new optimization strategies are essential to ensure the sustainability of transplantation as a curative treatment for advanced liver cirrhosis. The aim of this review was to summarize the effect of MASLD on the liver donor population, highlighting how to evaluate steatosis in donors, and to discuss its clinical implications as well as strategies to optimize organ allocation in the MASLD era.

13 September 2024 in Annals of Hepatology
Verified
Journal Article
Open access
ILICELA PALMA LARA
ICELA PALMA LARA
MOMA GUADALUPE ORTIZ
MA GUADALUPE ORTIZ
José Bonilla-DelgadoJosé Bonilla-Delgado
José Bonilla-Delgado
JPJuanita Pérez-Escobar
Juanita Pérez-Escobar
RGRicardo Godinez-Aguilar
Ricardo Godinez-Aguilar
CPCarmen Palacios-Reyes
Carmen Palacios-Reyes
Liver cirrhosis causes include alcoholism, viral infections (hepatitis B virus (HBV) and hepatitis C virus (HCV)), alcohol-associated liver disease (ALD), and metabolic dysfunction associated with steatotic liver disease (MASLD), among others. Cirrhosis frequency has increased in recent years, with a prevalence of 1395 cases per 100,000 and a mortality rate of 18 per 100,000, which corresponded to 1,472,000 deaths during 2017. In Mexico, liver disease is a public health problem since it was associated to 41,890 deaths in 2022, including liver cirrhosis (>25,000) and ALD (14,927). This represents 114 daily deaths due to these causes, and corresponds to the 4th or 5th place of all causes. The global prevalence of MASLD is estimated to affect 25% of the world's population, while in the pediatric population it could be higher. In Mexican population it is more prevalent since estimations were around 41.3% in 2023. Alcohol consumption, a global health issue due to its high prevalence and associated morbidities, is associated to ALD in 32.9%, with a mortality rate of 23.9%, primarily due to liver-related causes. In Mexico, ALD is present in 23% of all cirrhosis cases, already surpassed by hepatitis B cases in 2009. HCV and HBV frequencies changed due to programs implementing screening detection, vaccines and direct-acting antivirals during the last years. A switch of causes has occurred, increasing MASLD and diminishing viral causes. Efficient performed liver transplantation has grown as a response to increasing cirrhosis cases, including recent authorized centers. These efforts are necessary, whereas preventive strategies should be implemented according to leading causes.

15 November 2025 in Annals of Hepatology
Verified
Journal Article
Open access
JPJuanita Pérez-Escobar
Juanita Pérez-Escobar
RVRicardo Ivan Velazquez-Silva
Ricardo Ivan Velazquez-Silva
PCPaulina Carpinteyro-Espin
Paulina Carpinteyro-Espin
JGJosé Carlos Gasca-Aldama
José Carlos Gasca-Aldama